Genzyme, a Sanofi company, announced today that selected artwork
from Expression of Hope III will be featured through a travelling
exhibit and online gallery. Expression of Hope is a global disease
awareness program featuring works of art created by the community
of people affected by lysosomal storage disorders (LSD). This
unique program encourages anyone affected by an LSD to create and
submit a work of art that expresses their experiences of living
with these rare, inherited diseases.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20150520005144/en/
The 25 piece Expression of Hope III exhibit will open today at
Genzyme Center in Cambridge, Mass. The exhibit will travel to
patient meetings and conferences around the world in 2015 and 2016.
Initial exhibits include the National Niemann-Pick Disease
Foundation family conference in Chicago, Illinois, the Niemann-Pick
Disease Group – UK Family Conference in the United Kingdom, and the
Global Genes “Tribute to Champions of Hope” Gala in California.
Future exhibits are currently being planned for the Asia-Pacific
region and Latin America. All of the 168 artwork submissions,
including the 25 exhibit selections, can be viewed at
www.expressionofhope.com.
Working in collaboration with patient advocacy organizations
around the world, Expression of Hope III received submissions from
artists of all ages and artistic ability, including family members,
friends and healthcare workers from over 20 countries. The exhibit
artwork was selected by a panel of professional artists from the
Massachusetts area, including Lesley University’s Expressive
Therapies program, the DeCordova Museum, Massachusetts College of
Art and the Rocky Neck Arts Colony. This is the third Expression of
Hope campaign, with nearly 500 artwork submissions received since
the program first launched in in 2006.
“Artistic expression transcends barriers created by geography,
language, physical ability and age,” said Genzyme’s Head of Rare
Diseases, Richard Peters, M.D., Ph.D. “By sharing these reflections
of the human spirit with the world, the Expression of Hope artists
challenge and motivate thousands of people to better understand the
experience of living with an LSD.”
Lysosomal storage disorders, also known as lipid storage
disorders, are a group of inherited metabolic conditions in which
fatty materials (lipids) accumulate in various cells and tissues in
the body. People with these disorders either do not produce enough
of an enzyme required to break down (metabolize) lipids, or they
produce enzymes that do not work properly. Over time, the build-up
of lipids can lead to cellular and tissue damage, particularly in
the brain, peripheral nervous system, liver, spleen, and bone
marrow. Examples of LSDs include Gaucher, Fabry, Pompe, MPS and
Niemann-Pick diseases.
About Expression of Hope
Expression of Hope is a global program of inspiration and
awareness featuring works of art by the lysosomal storage disorder
community. In collaboration with LSD patient organizations around
the world, Genzyme launched the Expression of Hope program in 2006
to give those impacted by lysosomal storage disorders (LSDs) the
opportunity to raise awareness of these rare genetic diseases. More
than 100 patients and caregivers expressed their unique stories
through their original pieces of artwork. Building on that initial
success, Genzyme launched the second Expression of Hope program in
2009, and once again the global community responded with
enthusiasm, creativity and insight. Our third Expression of Hope
program further reinforces the commitment of individuals affected
by lysosomal storage disorders to building awareness and expressing
their unique stories through art. www.Expressionofhope.com
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of
transformative therapies for patients affected by rare and
debilitating diseases for over 30 years. We accomplish our goals
through world-class research and with the compassion and commitment
of our employees. With a focus on rare diseases and multiple
sclerosis, we are dedicated to making a positive impact on the
lives of the patients and families we serve. That goal guides and
inspires us every day. Genzyme’s portfolio of transformative
therapies, which are marketed in countries around the world,
represents groundbreaking and life-saving advances in medicine. As
a Sanofi company, Genzyme benefits from the reach and resources of
one of the world’s largest pharmaceutical companies, with a shared
commitment to improving the lives of patients. Learn more at
www.genzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation. All
rights reserved.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs.
Sanofi has core strengths in the field of healthcare with seven
growth platforms: diabetes solutions, human vaccines, innovative
drugs, consumer healthcare, emerging markets, animal health and
Genzyme.
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These statements include projections and
estimates and their underlying assumptions, statements regarding
plans, objectives, intentions and expectations with respect to
future financial results, events, operations, services, product
development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words "expects", "anticipates", "believes", "intends",
"estimates", "plans" and similar expressions. Although Sanofi's
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
the Group's ability to benefit from external growth opportunities,
trends in exchange rates and prevailing interest rates, the impact
of cost containment policies and subsequent changes thereto, the
average number of shares outstanding as well as those discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under "Risk Factors" and "Cautionary
Statement Regarding Forward-Looking Statements" in Sanofi's annual
report on Form 20-F for the year ended December 31, 2014. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150520005144/en/
Genzyme Media Contact:Lori Gorski,
617-768-9344lori.gorski@genzyme.comorSanofi Investor Relations
Contact:Sebastien Martel, +33 (0) 1.53.77.45.43IR@sanofi.com
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024